Cargando…

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT

In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that m...

Descripción completa

Detalles Bibliográficos
Autores principales: de Nonneville, Alexandre, Salas, Sébastien, Bertucci, François, Sobinoff, Alexander P, Adélaïde, José, Guille, Arnaud, Finetti, Pascal, Noble, Jane R, Churikov, Dimitri, Chaffanet, Max, Lavit, Elise, Pickett, Hilda A, Bouvier, Corinne, Birnbaum, Daniel, Reddel, Roger R, Géli, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549729/
https://www.ncbi.nlm.nih.gov/pubmed/35920001
http://dx.doi.org/10.15252/emmm.202215859
_version_ 1784805734781812736
author de Nonneville, Alexandre
Salas, Sébastien
Bertucci, François
Sobinoff, Alexander P
Adélaïde, José
Guille, Arnaud
Finetti, Pascal
Noble, Jane R
Churikov, Dimitri
Chaffanet, Max
Lavit, Elise
Pickett, Hilda A
Bouvier, Corinne
Birnbaum, Daniel
Reddel, Roger R
Géli, Vincent
author_facet de Nonneville, Alexandre
Salas, Sébastien
Bertucci, François
Sobinoff, Alexander P
Adélaïde, José
Guille, Arnaud
Finetti, Pascal
Noble, Jane R
Churikov, Dimitri
Chaffanet, Max
Lavit, Elise
Pickett, Hilda A
Bouvier, Corinne
Birnbaum, Daniel
Reddel, Roger R
Géli, Vincent
author_sort de Nonneville, Alexandre
collection PubMed
description In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high‐grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild‐type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT‐positive ATRX‐wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX‐mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX‐wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target.
format Online
Article
Text
id pubmed-9549729
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95497292022-10-14 TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT de Nonneville, Alexandre Salas, Sébastien Bertucci, François Sobinoff, Alexander P Adélaïde, José Guille, Arnaud Finetti, Pascal Noble, Jane R Churikov, Dimitri Chaffanet, Max Lavit, Elise Pickett, Hilda A Bouvier, Corinne Birnbaum, Daniel Reddel, Roger R Géli, Vincent EMBO Mol Med Articles In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high‐grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild‐type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT‐positive ATRX‐wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX‐mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX‐wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target. John Wiley and Sons Inc. 2022-08-03 /pmc/articles/PMC9549729/ /pubmed/35920001 http://dx.doi.org/10.15252/emmm.202215859 Text en © 2022 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
de Nonneville, Alexandre
Salas, Sébastien
Bertucci, François
Sobinoff, Alexander P
Adélaïde, José
Guille, Arnaud
Finetti, Pascal
Noble, Jane R
Churikov, Dimitri
Chaffanet, Max
Lavit, Elise
Pickett, Hilda A
Bouvier, Corinne
Birnbaum, Daniel
Reddel, Roger R
Géli, Vincent
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
title TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
title_full TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
title_fullStr TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
title_full_unstemmed TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
title_short TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
title_sort top3a amplification and atrx inactivation are mutually exclusive events in pediatric osteosarcomas using alt
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549729/
https://www.ncbi.nlm.nih.gov/pubmed/35920001
http://dx.doi.org/10.15252/emmm.202215859
work_keys_str_mv AT denonnevillealexandre top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT salassebastien top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT bertuccifrancois top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT sobinoffalexanderp top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT adelaidejose top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT guillearnaud top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT finettipascal top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT noblejaner top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT churikovdimitri top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT chaffanetmax top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT lavitelise top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT picketthildaa top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT bouviercorinne top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT birnbaumdaniel top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT reddelrogerr top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt
AT gelivincent top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt